S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:ABIO

ARCA biopharma - ABIO Stock Forecast, Price & News

$2.03
-0.04 (-1.93%)
(As of 03/28/2023 05:12 PM ET)
Add
Compare
Today's Range
$2.00
▼
$2.09
50-Day Range
$2.02
▼
$2.34
52-Week Range
$1.76
▼
$2.70
Volume
20,508 shs
Average Volume
32,002 shs
Market Capitalization
$29.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABIO stock logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

March 28, 2023 | americanbankingnews.com
ARCA biopharma (NASDAQ:ABIO) Research Coverage Started at StockNews.com
March 27, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO)
March 28, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
March 19, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on ARCA biopharma (NASDAQ:ABIO)
March 10, 2023 | msn.com
Can Frankie Muniz Contend at Phoenix After His Impressive ARCA Debut?
February 24, 2023 | finance.yahoo.com
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
February 18, 2023 | foxnews.com
Frankie Muniz finishes 11th in ARCA debut at Daytona International Speedway
February 14, 2023 | msn.com
ARCA gets funding for new 40-foot mobile clinic, helps end surge of drug overdose deaths in St. Louis region
March 28, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
January 11, 2023 | foxnews.com
Frankie Muniz to race in ARCA Menards Series
January 11, 2023 | benzinga.com
FRANKIE MUNIZ TAKES ON 2023 ARCA MENARDS SERIES CHAMPIONSHIP IN RETTE JONES RACING NO. 30 FORD MUSTANG
January 9, 2023 | msn.com
‘Goya, Carrière and the Ghost of Buñuel’ Wins Uruguay’s ARCA
January 2, 2023 | msn.com
Featuring ‘Caravaggio,’ ‘Charlotte,’ ‘Dreaming Walls,’ Uruguay’s ARCA Kicks Off Second Edition
December 19, 2022 | finance.yahoo.com
James Flynn Joins ARCA biopharma Board of Directors
November 14, 2022 | finance.yahoo.com
One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year
October 29, 2022 | finanznachrichten.de
ARCA biopharma, Inc.: ARCA biopharma Announces Third Quarter 2022 Financial Results
October 28, 2022 | finance.yahoo.com
ARCA biopharma Announces Third Quarter 2022 Financial Results
October 13, 2022 | msn.com
Mother, daughter set to compete in ARCA West race in Las Vegas
October 9, 2022 | foxnews.com
ARCA race ends with tempers flaring between Sammy Smith, Jesse Love
October 7, 2022 | msn.com
How to Watch NASCAR, Formula 1, ARCA and Everything Else in Racing This Weekend, October 8-9
September 20, 2022 | seekingalpha.com
ABIO ARCA biopharma, Inc.
September 15, 2022 | foxnews.com
ARCA driver Toni Breidinger becomes Victoria's Secret model: 'Little me is crying'
September 14, 2022 | msn.com
NASCAR returns to Milwaukee Mile with Craftsman Truck and ARCA series
September 11, 2022 | msn.com
Corey Heim bows out of ARCA series with Kansas Speedway win
September 4, 2022 | msn.com
Du Quoin State Fair ARCA Menards Series event postponed due to wet conditions
August 26, 2022 | tmcnet.com
SESAMI WELCOMES GLOBAL LEADER ARCA AS IT STRENGTHENS ITS GLOBAL LEADERSHIP IN CASH AUTOMATION SOLUTIONS
August 18, 2022 | msn.com
How to watch Watkins Glen ARCA Menards race: Time, TV channel, free live stream
See More Headlines
Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Company Calendar

Last Earnings
8/04/2021
Today
3/28/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
CUSIP
N/A
CIK
907654
Web
arcabio.com
Phone
(720) 940-2100
Fax
720-208-9261
Employees
17
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,930,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-22.39%
Return on Assets
-21.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
37.72
Quick Ratio
37.72

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
0.72

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
$29.97 million
Optionable
Not Optionable
Beta
1.47

Key Executives

  • Michael R. Bristow
    President, Chief Executive Officer & Director
  • Thomas A. Keuer
    Chief Operating Officer
  • C. Jeffrey Dekker
    Chief Financial Officer
  • Christopher David OzeroffChristopher David Ozeroff
    Secretary, Senior Vice President & General Counsel
  • Sharon Perry
    Vice President-Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ABIO Stock - Frequently Asked Questions

How have ABIO shares performed in 2023?

ARCA biopharma's stock was trading at $2.37 at the start of the year. Since then, ABIO stock has decreased by 12.7% and is now trading at $2.0691.
View the best growth stocks for 2023 here.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 226,300 shares, a decline of 7.1% from the February 28th total of 243,500 shares. Based on an average daily volume of 38,700 shares, the days-to-cover ratio is currently 5.8 days. Approximately 1.6% of the company's shares are short sold.
View ARCA biopharma's Short Interest.

When is ARCA biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our ABIO earnings forecast.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) released its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($2.37) by $2.03.

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (5.96%), Murchinson Ltd. (0.35%), Susquehanna International Group LLP (0.00%), Jane Street Group LLC (0.10%), SG3 Management LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway.
View institutional ownership trends.

How do I buy shares of ARCA biopharma?

Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.07.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $29.97 million. The biopharmaceutical company earns $-9,930,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 3/28/2023 by MarketBeat.com Staff